For example, a combination of costimulatory agonists anti-OX40 and anti-4-1BB mAbs with vaccine, in a breast Her-2/neu transgenic mouse model, enhanced both CD4+ and CD8+ T cell activity and proliferation associated with the retardation of tumor growth (62, 63). Here, TNFRSF4 is linked to neoplasm.